By Owen Tucker-Smith
OS Therapies shares surged Wednesday after the biotech company reported positive data from a clinical trial for its cancer treatment OST-HER2.
Shares of the N.Y., clinical-stage biotechnology company were recently up 60% to $6.64 in premarket trading, which is above the stock's 52-week high of $6.48.
The trial tested whether OST-HER2 could successfully treat a rare form of bone cancer that spreads to the lungs. The company reported statistically significant results in the study's primary endpoint, which measured whether patients went 12 months without the recurrence of metastatic osteosarcoma.
The company also indicated promising results from patients at the 1-year and 2-year marks.
Robert Petit, the company's chief medical and scientific officer, said that the treatment would help a population for whom there are currently no approved therapies.
OS Therapies said that it plans to seek U.S. FDA accelerated approval for OST-HER2.
Write to Owen Tucker-Smith at owen.tucker-smith@wsj.com
(END) Dow Jones Newswires
January 15, 2025 09:33 ET (14:33 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。